NXTC – Nextcure Inc
NXTC — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.98
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.24
EPS Last/This Y
12.72
EPS This/Next Y
-1.42
Price
7.84
Target Price
19.33
Analyst Recom
1
Performance Q
-40.77
Upside
-3,266.2%
Beta
1.44
Ticker: NXTC
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | NXTC | 12.07 | N/A | N/A | 0 |
| 2026-04-24 | NXTC | 10.8 | N/A | N/A | 0 |
| 2026-04-27 | NXTC | 9.74 | N/A | N/A | 0 |
| 2026-04-28 | NXTC | 9.495 | N/A | N/A | 0 |
| 2026-04-29 | NXTC | 8.97 | N/A | N/A | 0 |
| 2026-04-30 | NXTC | 9.42 | N/A | N/A | 0 |
| 2026-05-01 | NXTC | 9.65 | N/A | N/A | 0 |
| 2026-05-04 | NXTC | 9.01 | N/A | N/A | 0 |
| 2026-05-05 | NXTC | 9.43 | N/A | N/A | 0 |
| 2026-05-06 | NXTC | 10.54 | N/A | N/A | 0 |
| 2026-05-07 | NXTC | 10.17 | N/A | N/A | 0 |
| 2026-05-08 | NXTC | 10 | N/A | N/A | 0 |
| 2026-05-11 | NXTC | 9.74 | N/A | N/A | 0 |
| 2026-05-12 | NXTC | 9.9 | N/A | N/A | 0 |
| 2026-05-13 | NXTC | 9.86 | N/A | N/A | 0 |
| 2026-05-14 | NXTC | 10.11 | N/A | N/A | 0 |
| 2026-05-15 | NXTC | 9.83 | N/A | N/A | 0 |
| 2026-05-18 | NXTC | 9.32 | N/A | N/A | 0 |
| 2026-05-19 | NXTC | 9.13 | N/A | N/A | 0 |
| 2026-05-20 | NXTC | 9.81 | N/A | N/A | 0 |
| 2026-05-21 | NXTC | 10.13 | N/A | N/A | 0 |
| 2026-05-22 | NXTC | 7.84 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | NXTC | 12.23 | 61.3 | 45.0 | -8.21 |
| 2026-04-24 | NXTC | 10.49 | 61.3 | 55.9 | -8.21 |
| 2026-04-27 | NXTC | 9.57 | 61.3 | 62.5 | -8.21 |
| 2026-04-28 | NXTC | 9.40 | 61.3 | 62.9 | -8.21 |
| 2026-04-30 | NXTC | 9.31 | 61.3 | 63.2 | -8.21 |
| 2026-05-01 | NXTC | 9.46 | 61.3 | 61.6 | -8.21 |
| 2026-05-04 | NXTC | 8.96 | 61.3 | 65.9 | -8.21 |
| 2026-05-05 | NXTC | 9.43 | 61.3 | 61.7 | -8.21 |
| 2026-05-06 | NXTC | 10.60 | 61.3 | 57.7 | -8.21 |
| 2026-05-07 | NXTC | 10.06 | 61.3 | 58.3 | -8.21 |
| 2026-05-08 | NXTC | 9.93 | 61.3 | 59.3 | -8.21 |
| 2026-05-11 | NXTC | 9.86 | 61.3 | 59.2 | -8.98 |
| 2026-05-12 | NXTC | 9.62 | 56.6 | - | -8.98 |
| 2026-05-13 | NXTC | 9.90 | 56.6 | - | -8.98 |
| 2026-05-14 | NXTC | 10.48 | 56.6 | - | -8.98 |
| 2026-05-15 | NXTC | 9.51 | 56.6 | - | -7.69 |
| 2026-05-18 | NXTC | 9.41 | 83.7 | - | -7.69 |
| 2026-05-19 | NXTC | 9.17 | 83.7 | - | -7.69 |
| 2026-05-20 | NXTC | 9.43 | 83.5 | - | -6.93 |
| 2026-05-21 | NXTC | 10.60 | 83.5 | - | -6.93 |
| 2026-05-22 | NXTC | 7.84 | 83.5 | - | -6.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | NXTC | 0.00 | 17.58 | 2.33 |
| 2026-04-24 | NXTC | 0.00 | 17.58 | 2.33 |
| 2026-04-27 | NXTC | 0.00 | 17.58 | 3.03 |
| 2026-04-28 | NXTC | 0.00 | 17.58 | 3.03 |
| 2026-04-29 | NXTC | 0.00 | 17.58 | 3.03 |
| 2026-04-30 | NXTC | 0.00 | 17.58 | 3.03 |
| 2026-05-01 | NXTC | 0.00 | 17.58 | 3.03 |
| 2026-05-04 | NXTC | 0.00 | 17.33 | 3.03 |
| 2026-05-05 | NXTC | 0.00 | 17.33 | 3.03 |
| 2026-05-06 | NXTC | 0.00 | 17.33 | 3.03 |
| 2026-05-07 | NXTC | 0.00 | 17.33 | 3.03 |
| 2026-05-08 | NXTC | 0.00 | 17.33 | 3.03 |
| 2026-05-11 | NXTC | 0.00 | 17.30 | 2.99 |
| 2026-05-12 | NXTC | 0.00 | 17.30 | 2.99 |
| 2026-05-13 | NXTC | 0.00 | 17.30 | 2.99 |
| 2026-05-14 | NXTC | 0.00 | 17.30 | 2.99 |
| 2026-05-15 | NXTC | 0.00 | 17.30 | 2.99 |
| 2026-05-18 | NXTC | 0.00 | 17.16 | 2.98 |
| 2026-05-19 | NXTC | 0.00 | 17.16 | 2.98 |
| 2026-05-20 | NXTC | 0.00 | 17.16 | 2.98 |
| 2026-05-21 | NXTC | 0.00 | 17.16 | 2.98 |
| 2026-05-22 | NXTC | 0.00 | 17.16 | 2.98 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
22 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-1.87
Avg. EPS Est. Current Quarter
-1.86
Avg. EPS Est. Next Quarter
-1.63
Insider Transactions
Institutional Transactions
17.16
Beta
1.44
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
3
Growth Score
18
Sentiment Score
92
Actual DrawDown %
92.9
Max Drawdown 5-Year %
-97
Target Price
19.33
P/E
Forward P/E
PEG
P/S
P/B
1.06
P/Free Cash Flow
EPS
-19.07
Average EPS Est. Cur. Y
-6.93
EPS Next Y. (Est.)
-8.35
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.91
Return on Equity vs Sector %
-231.7
Return on Equity vs Industry %
-216.1
EPS 1 7Days Diff
0.8
EPS 1 30Days Diff
1.28
EBIT Estimation
◆
NXTC
Healthcare
$7.83
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
15/25
Volume
3/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
36.4
Range 1M
1.5%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
18/25
Growth
17/30
Estimates
0/20
Inst/Vol
9/15
Options
0/10
EPS Yr
62.7%
EPS NY
-13.9%
52W%
29%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+146.9% upside
Quality
2/30
Valuation
16/30
Growth
10/25
Stability
7/10
LT Trend
4/5
Upside
+146.9%
Quality
3
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 40
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC
Latest News
—
Caricamento notizie per NXTC…
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading